

Mark R Lackner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5446689/publications.pdf>

Version: 2024-02-01

64
papers

6,416
citations

93792

39
h-index

129628

63
g-index

66
all docs

66
docs citations

66
times ranked

12062
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 292-303.	1.9	9
2	Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 844-850.	1.6	12
3	Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 770-781.	1.2	20
4	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms. <i>Cancer Research</i> , 2019, 79, 3916-3927.	0.4	26
5	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4431-4442.	3.2	40
6	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
7	Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. <i>Clinical Cancer Research</i> , 2019, 25, 2254-2263.	3.2	62
8	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. <i>Npj Precision Oncology</i> , 2018, 2, 7.	2.3	107
9	Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 686-702.	1.2	149
10	A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017, 22, 1491-1499.	1.9	23
11	High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 921-932.	1.2	17
12	The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. <i>ELife</i> , 2016, 5, .	2.8	100
13	Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. <i>PLoS ONE</i> , 2016, 11, e0165856.	1.1	1
14	A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1493-1501.	3.3	57
15	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 811-821.	5.1	239
16	A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). <i>Cancer</i> , 2016, 122, 3519-3528.	2.0	58
17	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. <i>Npj Breast Cancer</i> , 2016, 2, 16022.	2.3	21
18	Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. <i>Nature Communications</i> , 2016, 7, 11579.	5.8	244

#	ARTICLE	IF	CITATIONS
19	CTCs for Biomarker and Companion Diagnostic Development. <i>Current Cancer Research</i> , 2016, , 293-313.	0.2	0
20	Activating Mutations in <i>PIK3CB</i> Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110 β . <i>Cancer Research</i> , 2016, 76, 1193-1203.	0.4	52
21	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1987-1994.	0.8	84
22	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	0.8	99
23	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. <i>Clinical Cancer Research</i> , 2015, 21, 4305-4311.	3.2	51
24	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 77-86.	3.2	265
25	PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
26	Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2941-2951.	3.2	90
27	Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer. <i>British Journal of Cancer</i> , 2015, 113, 970-978.	2.9	21
28	Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers. <i>PLoS ONE</i> , 2014, 9, e88401.	1.1	30
29	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 315-325.	1.1	24
30	Changing the paradigm: circulating tumor DNA as a "liquid biopsy" for clinical biomarker assessments. <i>Clinical Investigation</i> , 2014, 4, 1083-1093.	0.0	1
31	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing. <i>Clinical Cancer Research</i> , 2014, 20, 2080-2091.	3.2	57
32	Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 336-343.	1.9	52
33	Changes in <i>PIK3CA</i> mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 211-219.	1.1	36
34	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	0.8	12
35	Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma. <i>Journal of Translational Medicine</i> , 2013, 11, 76.	1.8	8
36	Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068. <i>Clinical Cancer Research</i> , 2013, 19, 6976-6986.	3.2	72

#	ARTICLE	IF	CITATIONS
37	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1122-1130.	1.9	22
38	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. <i>Clinical Cancer Research</i> , 2012, 18, 6771-6783.	3.2	156
39	FOXO3a and β -catenin co-localization: double trouble in colon cancer?. <i>Nature Medicine</i> , 2012, 18, 854-856.	15.2	14
40	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. <i>Clinical Cancer Research</i> , 2012, 18, 2391-2401.	3.2	387
41	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1143-1154.	1.9	184
42	Monitoring Phosphoproteomic Response to Targeted Kinase Inhibitors Using Reverse-Phase Protein Microarrays. <i>Methods in Molecular Biology</i> , 2012, 795, 203-215.	0.4	3
43	Mechanisms of acquired resistance to targeted cancer therapies. <i>Future Oncology</i> , 2012, 8, 999-1014.	1.1	150
44	Challenges and Opportunities in the Use of CTCs for Companion Diagnostic Development. <i>Recent Results in Cancer Research</i> , 2012, 195, 241-253.	1.8	4
45	GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2426-2436.	1.9	210
46	TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer. <i>Science Signaling</i> , 2011, 4, ra41.	1.6	252
47	miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer A presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011. This Presentation also complements the <i>Science Signaling</i> Research Article by Stinson et al. published 14 June 2011. <i>Science Signaling</i> , 2011, 4, pt5.	1.6	109
48	Molecular Biomarker Analyses Using Circulating Tumor Cells. <i>PLoS ONE</i> , 2010, 5, e12517.	1.1	271
49	Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3-Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models. <i>Clinical Cancer Research</i> , 2010, 16, 3670-3683.	3.2	247
50	Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 2512-2517.	3.2	123
51	Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 75-87.	1.5	18
52	In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. <i>Clinical Cancer Research</i> , 2009, 15, 4649-4664.	3.2	434
53	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression. <i>Cancer Research</i> , 2009, 69, 3042-3051.	0.4	164
54	Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2110-2121.	1.9	78

#	ARTICLE	IF	CITATIONS
55	A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 290-297.	1.2	12
56	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. <i>Molecular Cancer Research</i> , 2009, 7, 511-522.	1.5	201
57	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer. <i>Cancer Research</i> , 2008, 68, 5380-5389.	0.4	102
58	Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2599-2608.	1.9	36
59	Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3695-3706.	1.9	73
60	Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. <i>Cancer Cell</i> , 2005, 7, 325-336.	7.7	131
61	Facilitation of Synaptic Transmission by EGL-30 Gq \pm and EGL-8 PLC $\hat{1}^2$. <i>Neuron</i> , 1999, 24, 335-346.	3.8	318
62	MAP Kinase Signaling Specificity Mediated by the LIN-1 Ets/LIN-31 WH Transcription Factor Complex during <i>C. elegans</i> Vulval Induction. <i>Cell</i> , 1998, 93, 569-580.	13.5	189
63	Genetic Analysis of the <i>Caenorhabditis elegans</i> MAP Kinase Gene <i>mpk-1</i> . <i>Genetics</i> , 1998, 150, 103-117.	1.2	106
64	A MAP kinase homolog, <i>mpk-1</i> , is involved in ras-mediated induction of vulval cell fates in <i>Caenorhabditis elegans</i> . <i>Genes and Development</i> , 1994, 8, 160-173.	2.7	205